TAK1 deficiency attenuates cisplatin-induced acute kidney injury

Am J Physiol Renal Physiol. 2020 Jan 1;318(1):F209-F215. doi: 10.1152/ajprenal.00516.2019. Epub 2019 Dec 9.

Abstract

Cisplatin can cause acute kidney injury (AKI), but the molecular mechanisms are not well understood. The objective of the present study was to examine the role of transforming growth factor-β-activated kinase-1 (TAK1) in the pathogenesis of cisplatin-induced AKI. Wild-type mice and proximal tubule TAK1-deficient mice were treated with vehicle or cisplatin. Compared with wild-type control mice, proximal tubule TAK1-deficient mice had less severe kidney dysfunction, tubular damage, and apoptosis after cisplatin-induced AKI. Furthermore, conditional disruption of TAK1 in proximal tubular epithelial cells reduced caspase-3 activation, proinflammatory molecule expression, and JNK phosphorylation in the kidney in cisplatin-induced AKI. Taken together, cisplatin activates TAK1-JNK signaling pathway to promote tubular epithelial cell apoptosis and inflammation in cisplatin-induced AKI. Targeting TAK1 could be a novel therapeutic strategy against cisplatin-induced AKI.

Keywords: acute kidney injury; apoptosis; c-Jun NH2-terminal kinase; chemokines; cytokines; transforming growth factor-β-activated kinase-1.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Acute Kidney Injury / chemically induced
  • Acute Kidney Injury / genetics*
  • Acute Kidney Injury / metabolism
  • Acute Kidney Injury / pathology
  • Animals
  • Antineoplastic Agents / adverse effects*
  • Apoptosis / genetics
  • Cisplatin / adverse effects*
  • Epithelial Cells / pathology
  • Kidney / metabolism*
  • Kidney / pathology
  • MAP Kinase Kinase Kinases / genetics*
  • MAP Kinase Kinase Kinases / metabolism
  • Mice
  • Mice, Knockout
  • Phosphorylation

Substances

  • Antineoplastic Agents
  • MAP Kinase Kinase Kinases
  • MAP kinase kinase kinase 7
  • Cisplatin